<PAPER><mode2 name='PMC4153851' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Neurology</journal-id><journal-id journal-id-type='iso-abbrev'>Neurology</journal-id><journal-id journal-id-type='hwp'>neurology</journal-id><journal-id journal-id-type='publisher-id'>neur</journal-id><journal-id journal-id-type='pmc'>neurology</journal-id><journal-id journal-id-type='publisher-id'>NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type='ppub'>0028-3878</issn><issn pub-type='epub'>1526-632X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4153851</article-id><article-id pub-id-type='pmid'>25098535</article-id><article-id pub-id-type='publisher-id'>NEUROLOGY2014574723</article-id><article-id pub-id-type='doi'>10.1212/WNL.0000000000000755</article-id><article-categories><subj-group subj-group-type='hwp-journal-coll'><subject>25</subject><subject>26</subject></subj-group><subj-group subj-group-type='heading'><subject>Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Vitamin D and the risk of dementia and Alzheimer disease</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Littlejohns</surname><given-names>Thomas J.</given-names></name><degrees>MSc</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Henley</surname><given-names>William E.</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) UK Medical Research Council, grant number G0902158, Principal Investigator, 2010-2014.</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Lang</surname><given-names>Iain A.</given-names></name><degrees>PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) UK National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula (PenCLAHRC), n/a, Senior Lecturer, 2009-2013 and 2014-2018 (2) UK National Institute for Health Research (NIHR) Knowledge Mobilisation Fellowship, n/a, Fellow, 2014-2017</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Annweiler</surname><given-names>Cedric</given-names></name><degrees>MD, PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>- Travel grant: “Alzheimerï¿½s Association International Conference (AAIC) Fellowship Committee” grant (Vancouver, BC, Canada, July 2012).</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>- Gï¿½riatrie, Psychologie et Neuropsychiatrie du Vieillissement, Associate Editor, since 2012 - Journal of Alzheimer's Disease, Associate Editor, since 2012</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Beauchet</surname><given-names>Olivier</given-names></name><degrees>MD, PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>editorial advisory board member of Geriatr Psychol Neuropsychiatr Vieil</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>Consultancies for the Korian group,Ipsen Pharma, MSD and ï¿½rontolopï¿½le autonomie longï¿½vitï¿½ des Pays de la Loire</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Chaves</surname><given-names>Paulo H.M.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>American Journal of Epidemiology, Associate Editor, 2012-present; no compensation Journal of Epidemiology (Japan Epidemiological Association), Associate Editor, 2011-present - no compensation</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Fried</surname><given-names>Linda</given-names></name><degrees>MD, MPH</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>Employed by nonprofit university: Columbia University, Dean and DeLamar Professor of Public Health</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>Sanofi-Aventis</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>Sanofi-Aventis (consulting)</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>(1) National Institute on Aging, 1U01AG032947-01, Subcontract PI (prime: Johns Hopkins, University), 9/30/08-8/31/2011 (2) National Institute on Aging, 5R37AG019905-10, PI, 9/1/10-8/31/12 (3) National Institute on Aging, 5P01AG027735-05, Subcontract PI (prime: Johns Hopkins University), 8/01/08-6/30/12</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Kestenbaum</surname><given-names>Bryan R.</given-names></name><degrees>MD, MS</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>Kestenbaum, B., et al. (2009). Epidemiology and biostatistics : an introduction to clinical research. Dordrecht ; New York, Springer.</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>Daiichi Sankyo Pharmaceuticals Inc. A74915 (Giachelli, PI) 05/01/2012 ï¿½ 04/30/2014 0.1 calendar ï¿½Candidate vascular calcification genes in human smooth muscle tissueï¿½ $227,273 Role: Co-investigator</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NIH funding: NIH/NIDDK 1 R01DK094891-01 (Kestenbaum, PI) 09/01/2012 ï¿½ 08/31/2015 3.6 calendar ï¿½Mineral Metabolism disturbances and arteriovenous fistula maturationï¿½ $217,500 Role: Principal investigator This 3-year project will evaluate whether mineral metabolism plays a role in arteriovenous fistula maturation.NIH/NHLBI 1 R01 HL096875 (Kestenbaum, de Boer, Co- PIs) 04/01/2010 ï¿½ 06/30/2014 2.4 calendar ï¿½Phosphorous, vitamin D, and cardiovascular outcomesï¿½ $416,729 Role: Co- Role: Principal Investigator This 4-year project evaluates a comprehensive panel of serum and urine markers of mineral metabolism in association with clinical and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis.NIH/NIDDK 1 R21-DK081315-01A2 (Kestenbaum, PI) 07/01/2011 ï¿½ 08/31/2014 1.2 calendar ï¿½Serum calcification activity in patients with chronic kidney diseaseï¿½ $125,000 Role: Principal investigator This 2-year project will develop a novel serum calcification assay for patients with chronic kidney disease. NIH/NIDDK 1 R01DK087726 (de Boer, PI) 07/01/2010 ï¿½ 07/31/2014 1.2 calendarï¿½Insulin Resistance in chronic kidney diseaseï¿½ $294,202 Role: Key PersonnelThis 4-year project will comprehensively characterize insulin sensitivity, beta-cell function, and glucose tolerance using gold-standard methods among individuals who have moderate-severe chronic kidney disease.NIH/NHLBI R01 DK102134 (Young, PI) 09/01/2013 ï¿½ 08/31/2016 0.6 calendar ï¿½CKD targeted analyses of the Jackson Heart Studyï¿½ Role: Co-investigator This 3-year project will determine novel and traditional risk factors for kidney disease progression and cardiovascular complications of kidney disease among African Americans in the Jackson Heart Study. NIH/NIDDK 1 R01DK094434 (Rosenfeld, PI) 08/01/2012 ï¿½ 06/30/2017 0.6 calendar RANK-RANKL and vascular complications in chronic kidney disease $205,285 Role: Co-investigator This 5-year project combines laboratory and translational methods to determine the role of receptor activator of NFkB ligand (RANKL) in accelerated atherosclerosis of moderate-severe chronic kidney disease.</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Kuller</surname><given-names>Lewis H.</given-names></name><degrees>MD, DrPH</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Langa</surname><given-names>Kenneth M.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NIH, AG009740, Co-Investigator</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Lopez</surname><given-names>Oscar L.</given-names></name><degrees>MD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>Lundbeck,Lilly,Baxter, Grifols,Cognoptix</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NIA: P50 AG05133-27</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Kos</surname><given-names>Katarina</given-names></name><degrees>MD, PhD</degrees><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author'><name><surname>Soni</surname><given-names>Maya</given-names></name><degrees>PhD</degrees><xref rid='fn1' ref-type='author-notes'>*</xref><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Llewellyn</surname><given-names>David J.</given-names></name><degrees>PhD</degrees><xref rid='fn1' ref-type='author-notes'>*</xref><author-comment content-type='disclosure'><p><list list-type='order'><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>(1) Roche, conference travel, (2) DSM, workshop travel and speaker honorarium.</p></list-item></list></p><p><list list-type='order'><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Alzheimer's Association (NIRG-11-200737), (2) Norman Family Charitable Trust, (3) Age Related Diseases and Health Trust, (4) Sir Halley Stewart Trust, Lord Clinton's Charitable Trust, (5) RD&amp;E Foundation Trust, (6) UK National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care for the South West Peninsula (PenCLAHRC)</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type='order'><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the University of Exeter Medical School (T.J.L., W.E.H., I.A.L., K.K., M.S., D.J.L.), Exeter, UK; Department of Internal Medicine and Geriatrics (C.A., O.B.), Angers University Hospital, Angers, France; Herbert Wertheim College of Medicine (P.H.M.C.), Florida International University, Miami; Mailman School of Public Health (L.F.), Columbia University, New York; Kidney Research Institute, Division of Nephrology (B.R.K.), University of Washington, Seattle; Departments of Epidemiology (L.H.K.) and Neurology and Psychiatry (O.L.L.), University of Pittsburgh, PA; Division of General Medicine (K.M.L.), Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, MI; and the Institute for Social Research and the Institute for Healthcare Policy and Innovation (K.M.L.), University of Michigan, Ann Arbor.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Llewellyn: <email>david.llewellyn@exeter.ac.uk</email></corresp><fn fn-type='financial-disclosure'><p>Go to <ext-link ext-link-type='uri' xlink:href='http://neurology.org/'>Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by The National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South West Peninsula.</p></fn><fn id='fn1' fn-type='other'><label>*</label><p>These authors contributed equally to the manuscript.</p></fn></author-notes><pub-date pub-type='ppub'><day>2</day><month>9</month><year>2014</year></pub-date><pub-date pub-type='pmc-release'><day>2</day><month>9</month><year>2014</year></pub-date><volume>83</volume><issue>10</issue><fpage>920</fpage><lpage>928</lpage><history><date date-type='received'><day>03</day><month>2</month><year>2014</year></date><date date-type='accepted'><day>28</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 American Academy of Neurology</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type='open-access'><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:type='simple' xlink:title='pdf' xlink:href='NEUROLOGY2014574723.pdf'></self-uri><abstract><sec><title>Objective:</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>To determine whether low vitamin D concentrations are associated with an increased risk of incident all-cause dementia and Alzheimer disease.</s></p></sec><sec><title>Methods:</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>One thousand six hundred fifty-eight elderly ambulatory adults free from dementia, cardiovascular disease, and stroke who participated in the US population–based Cardiovascular Health Study between 1992–1993 and 1999 were included.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Serum 25-hydroxyvitamin D (25(OH)D) concentrations were determined by liquid chromatography-tandem mass spectrometry from blood samples collected in 1992–1993.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Incident all-cause dementia and Alzheimer disease status were assessed during follow-up using National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria.</s></p></sec><sec><title>Results:</title><p><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>During a mean follow-up of 5.6 years, 171 participants developed all-cause dementia, including 102 cases of Alzheimer disease.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Using Cox proportional hazards models, the multivariate adjusted hazard ratios (95% confidence interval [CI]) for incident all-cause dementia in participants who were severely 25(OH)D deficient (&lt;25 nmol/L) and deficient (≥25 to &lt;50 nmol/L) were 2.25 (95% CI: 1.23–4.13) and 1.53 (95% CI: 1.06–2.21) compared to participants with sufficient concentrations (≥50 nmol/L).</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The multivariate adjusted hazard ratios for incident Alzheimer disease in participants who were severely 25(OH)D deficient and deficient compared to participants with sufficient concentrations were 2.22 (95% CI: 1.02–4.83) and 1.69 (95% CI: 1.06–2.69).</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In multivariate adjusted penalized smoothing spline plots, the risk of all-cause dementia and Alzheimer disease markedly increased below a threshold of 50 nmol/L.</s></p></sec><sec><title>Conclusion:</title><p><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Our results confirm that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and Alzheimer disease.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This adds to the ongoing debate about the role of vitamin D in nonskeletal conditions.</s></p></sec></abstract></article-meta></front><body><p><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Recent meta-analyses confirm that low serum vitamin D concentrations are associated with prevalent Alzheimer disease (AD) dementia and cognitive impairment.<sup><xref rid='R1' ref-type='bibr'>1</xref><xref rid='R2' ref-type='bibr'>–</xref><xref rid='R3' ref-type='bibr'>3</xref></sup></s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This is cause for concern given the high rates of vitamin D deficiency in older adults<sup><xref rid='R4' ref-type='bibr'>4</xref></sup> and continued uncertainty about the causes of AD and other forms of dementia.<sup><xref rid='R5' ref-type='bibr'>5</xref></sup></s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Both the 1,25-dihydroxyvitamin D3 receptor and 1α-hydroxylase, the enzyme responsible for synthesizing the bioactive form of vitamin D, are found throughout the human brain.<sup><xref rid='R6' ref-type='bibr'>6</xref></sup></s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In vitro, vitamin D increases the phagocytic clearance of amyloid plaques by stimulating macrophages<sup><xref rid='R7' ref-type='bibr'>7</xref>,<xref rid='R8' ref-type='bibr'>8</xref></sup> and reduces amyloid-induced cytotoxicity and apoptosis in primary cortical neurons.<sup><xref rid='R9' ref-type='bibr'>9</xref></sup></s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Vitamin D deficiency has also been linked to vascular dysfunction and ischemic stroke risk<sup><xref rid='R10' ref-type='bibr'>10</xref></sup> as well as brain atrophy.<sup><xref rid='R11' ref-type='bibr'>11</xref></sup></s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, reverse causation is also possible, as the onset of dementia may lead to dietary changes and reduced outdoor activity, which in turn result in lower vitamin D concentrations.<sup><xref rid='R12' ref-type='bibr'>12</xref></sup></s></p><p><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Previous prospective studies have established that low vitamin D concentrations in elderly adults are associated with an increased risk of cognitive decline.<sup><xref rid='R3' ref-type='bibr'>3</xref>,<xref rid='R13' ref-type='bibr'>13</xref><xref rid='R14' ref-type='bibr'>–</xref><xref rid='R15' ref-type='bibr'>15</xref></sup></s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Furthermore, it has been hypothesized that the risk of cognitive decline markedly increases below a threshold between 25 and 50 nmol/L.<sup><xref rid='R12' ref-type='bibr'>12</xref></sup></s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, preliminary prospective studies of vitamin D and dementia risk have been discordant.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a small study of 40 high-functioning elderly women, severe vitamin D deficiency (&lt;25 nmol/L) was associated with a higher risk of non-AD dementias but not AD over 7 years.<sup><xref rid='R16' ref-type='bibr'>16</xref></sup></s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In contrast, in 10,186 individuals, severe vitamin D deficiency was associated with medical records indicating AD but not vascular dementia over 30 years of follow-up.<sup><xref rid='R17' ref-type='bibr'>17</xref></sup></s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The discrepancy in these findings may be due to a lack of statistical power<sup><xref rid='R16' ref-type='bibr'>16</xref></sup> or use of unstandardized dementia diagnoses from medical records, which may result in considerable misclassification.<sup><xref rid='R17' ref-type='bibr'>17</xref></sup></s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> We therefore conducted what is to our knowledge the first large, prospective, population-based study incorporating a comprehensive adjudicated assessment of dementia and AD to examine their relationship with vitamin D concentrations.</s></p><sec sec-type='methods' id='s1'><title>METHODS</title><sec id='s1-1'><title>Participants.</title><p><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Participants were selected from the Cardiovascular Health Study (CHS), a large, prospective, population-based study in the United States designed to investigate the underlying causes of cardiovascular disease in older men and women.<sup><xref rid='R18' ref-type='bibr'>18</xref></sup></s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The CHS recruited participants from 4 communities: Forsyth county, NC (36.1° north, 80.3° west); Sacramento county, CA (38.5° north, 121.4° west); Washington county, MD (39.6° north, 77.8° west); and Pittsburgh, PA (40.4° north, 80.0° west).</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The cohort consisted of 5,201 adults recruited in 1989–1990 and an additional 687 African-American participants recruited in 1992–1993.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Of these 5,888 participants, 4,692 ambulatory participants had complete exam data in 1992–1993 (the baseline assessment for the current study).</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Serum 25-hydroxyvitamin D (25(OH)D) concentrations were not measured in 1,424 participants who had prevalent cardiovascular disease or stroke (one or more of the following: coronary heart disease, congestive heart failure, claudication, atrial fibrillation, pacemaker, implantable cardioverter defibrillator, stroke, or TIA), determined by medical records, ECG findings, and self-report.<sup><xref rid='R19' ref-type='bibr'>19</xref></sup></s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Further exclusions were insufficient serum volumes for vitamin D assay to be performed (&lt;500 µL; n = 945) and missing adjudicated dementia status (n = 596).<sup><xref rid='R20' ref-type='bibr'>20</xref></sup></s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Participants with prevalent dementia at the time of the vitamin D collection (n = 69) were excluded from the main analyses but included in secondary analyses of prevalent dementia.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> This resulted in a final sample of 1,658 participants for the main prospective analyses and 1,727 participants for the secondary baseline analyses.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Those lost to follow-up (defined as participants with serum 25(OH)D measured but no diagnostic assessment of incident dementia) were older (mean [SD], 74.3 [5.4] years vs 73.8 [4.6] years, <italic>p</italic> = 0.03), were more likely to be nonwhite (20.0% vs 13.1%, <italic>p</italic> &lt; 0.001), and had lower serum 25(OH)D concentrations (mean [SD], 61.2 [39.4] nmol/L vs 64.4 [26.5] nmol/L, <italic>p</italic> = 0.03), but they were no more likely to be female (71.4% vs 69.2%, <italic>p</italic> = 0.31) or less educated (27.4% vs 23.4% did not finish high school, 53% vs 54% finished high school/some college/vocational qualifications, and 19.6% vs 22.6% completed college or professional qualifications, <italic>p</italic> = 0.10).</s></p></sec><sec id='s1-2'><title>Standard protocol approvals, registrations, and patient consents.</title><p><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The institutional review boards at each participating institution approved the research protocols, and all participants provided written informed consent.</s></p></sec><sec id='s1-3'><title>Serum 25(OH)D measurement.</title><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Serum samples collected in 1992–1993 were stored at −70 °C at the Laboratory for Clinical Biochemistry Research at the University of Vermont, and measurements were performed by the University of Washington Clinical Nutrition Research Unit in 2008.<sup><xref rid='R21' ref-type='bibr'>21</xref></sup></s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Total 25(OH)D (the sum of 25(OH)D<sub>2</sub> and 25(OH)D<sub>3</sub>) was measured using liquid chromatography-tandem mass spectrometry (LC-MS) on a Waters Quattro micro mass spectrometer (Waters, Milford, MA); the interassay coefficient of variation was &lt;3.4%.<sup><xref rid='R19' ref-type='bibr'>19</xref></sup></s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Calibration of serum 25(OH)D concentrations was verified using SRM 972 from the National Institute of Standards and Technology.<sup><xref rid='R22' ref-type='bibr'>22</xref></sup></s></p></sec><sec id='s1-4'><title>Diagnosis of all-cause dementia and AD.</title><p><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Dementia and AD status was assessed in 1998–1999 by a committee of neurologists and psychiatrists on the basis of annual cognitive assessments, repeat MRI scans, medical records, questionnaires, and proxy interviews.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Diagnosis of dementia was based on a progressive or static cognitive deficit with impairment in at least 2 cognitive domains and a history of normal cognitive function before the onset of abnormalities.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Incident all-cause dementia and AD were diagnosed according to the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Further details can be found elsewhere.<sup><xref rid='R23' ref-type='bibr'>23</xref></sup></s></p></sec><sec id='s1-5'><title>Covariates.</title><p><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We adjusted for covariates identified as potential confounders<sup><xref rid='R1' ref-type='bibr'>1</xref><xref rid='R2' ref-type='bibr'>–</xref><xref rid='R3' ref-type='bibr'>3</xref>,<xref rid='R12' ref-type='bibr'>12</xref></sup>: age in years, season of blood collection (December–February, March–May, June–August, September–November), education status (did not finish high school, finished high school/some college/vocational qualifications, completed college/professional qualifications), sex, body mass index (BMI in kg/m<sup>2</sup>), smoking (nonsmoker, current smoker), alcohol consumption (National Institute on Alcohol Abuse and Alcoholism definitions: nondrinkers, moderate drinkers [women ≤7 drinks/week; men ≤14 drinks/week], heavy drinkers [women &gt;7 drinks/week; men &gt;14 drinks/week]), and significant depressive symptoms (score ≥8 on the revised 10-item Center for Epidemiologic Studies Depression Scale<sup><xref rid='R24' ref-type='bibr'>24</xref></sup>).</s></p></sec><sec id='s1-6'><title>Statistical analysis.</title><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Cox proportional hazards models were used to assess the associations between baseline serum 25(OH)D and the risk of incident all-cause dementia and AD.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Participants were considered at risk for dementia from baseline (1992–1993) and were censored at death or the end of follow-up in June 1999.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> All-cause dementia included AD cases, and analyses for AD were censored for non-AD dementia.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The proportionality of hazards assumption was assessed using the Schoenfeld residuals technique.<sup><xref rid='R25' ref-type='bibr'>25</xref></sup></s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We analyzed serum 25(OH)D using clinically relevant cutpoints: &lt;25 nmol/L (severely deficient), ≥25 nmol/L to &lt;50 nmol/L (deficient), and ≥50 nmol/L (sufficient).<sup><xref rid='R26' ref-type='bibr'>26</xref></sup></s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Linear trends across categories were tested by entering 25(OH)D groups into models as a continuous rather than a categorical variable.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In basic adjusted models, we controlled for age and season of blood collection.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In fully adjusted models, we controlled for education, sex, BMI, smoking, alcohol consumption, and depressive symptoms.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To investigate any threshold, we used multivariate adjusted penalized smoothing spline plots.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Eight outlying participants with 25(OH)D concentrations between 170 and 283 nmol/L were excluded due to imprecision at the extreme end of the distribution (none developed dementia during follow-up).</s></p><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>In secondary analyses, serum 25(OH)D concentrations were analyzed as a continuous rather than a categorical variable.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> 25(OH)D concentrations were standardized to have a mean of 0 and an SD of 1 to aid interpretation.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Because 25(OH)D concentrations were positively skewed, they were normalized using a log transformation.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We repeated the main analyses to include adjustments for health conditions that have been identified as potential mediators for the association between serum 25(OH)D concentrations and dementia risk<sup><xref rid='R12' ref-type='bibr'>12</xref>,<xref rid='R13' ref-type='bibr'>13</xref></sup>: diabetes (American Diabetes Association guidelines: using oral hypoglycemic agents or insulin, or plasma fasting glucose ≥7.0 nmol/L) and/or hypertension (3 categories; no hypertension: systolic &lt;140 mm Hg and diastolic &lt;90 mm Hg; treated hypertension: hypertensive medication; untreated hypertension: systolic ≥140 mm Hg or diastolic ≥90 mm Hg with no hypertensive medication).</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also adjusted for ethnicity (white/black) and examined potential interactions with ethnicity in separate models, although it is recognized that this may represent overadjustment.<sup><xref rid='R27' ref-type='bibr'>27</xref></sup></s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In a further analysis, we adjusted for socioeconomic status indicators: annual income (&lt;$12,000, $12,000–24,999, $25,000–49,999, ≥$50,000, missing) and usual lifetime occupation (professional/technical/managerial/administrative, sales/clerical service, craftsman/machine operator/laborer/farming/forestry, housewife, other/missing).</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Multivariate adjusted logistic regression models were used to investigate the cross-sectional association between serum 25(OH)D and prevalent all-cause dementia (n = 69) and AD (n = 34).</s></p><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>In sensitivity analyses, we excluded participants who developed all-cause dementia (n = 12) and AD (n = 6) within 1 year of baseline to remove the possibility that any association observed was determined by these “early converters.” <italic>p</italic> Values were 2-sided throughout, and the type I error rate for statistical significance was set at 0.05.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Analyses were performed using Stata SE version 12 (StataCorp, College Station, TX) with the exception of the spline plots, which were fitted in R version 2.15.1 (<ext-link ext-link-type='uri' xlink:href='http://www.r-project.org'>www.r-project.org</ext-link>).<xref rid='T1' ref-type='table'>Table 1</xref></s></p></sec></sec><sec sec-type='results' id='s2'><title>RESULTS</title><p><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> displays baseline characteristics for the study population included in the main prospective analyses.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Participants were followed up for a mean of 5.6 years (SD 1.6, median 6.1, range 0.1–8.4).</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> During 9,317.5 person-years of follow-up, 171 participants developed all-cause dementia and 102 developed AD.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The risk of developing both all-cause dementia and AD was significantly higher in participants who were either 25(OH)D deficient or severely deficient (<xref rid='T2' ref-type='table'>table 2</xref>).</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In minimally adjusted models, those who were deficient had about a 51% increased risk of all-cause dementia, whereas the increased risk for those who were severely deficient was about 122%.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The strength of the association observed for incident AD was similar to that observed for all-cause dementia.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Additional adjustment for potential confounders did not alter the pattern of results, and there was a linear trend across groups in all analyses, suggesting a monotonic association.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Kaplan-Meier plots for unadjusted rates of incident all-cause dementia and AD show clear differences in risk by 25(OH)D concentrations after 2–3 years of follow-up (<xref rid='F1' ref-type='fig'>figure 1</xref>).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Multivariate adjusted smoothing spline plots suggest that the risk of all-cause dementia and AD markedly increases at 25(OH)D concentrations below 50 nmol/L (<xref rid='F2' ref-type='fig'>figure 2</xref>).</s></p><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Baseline characteristics of 1,658 CHS participants by serum 25(OH)D concentration</p></caption><graphic xlink:href='NEUROLOGY2014574723TT1'></graphic></table-wrap><table-wrap id='T2' position='float'><label>Table 2</label><caption><p>Cox proportional hazards regression models of incident all-cause dementia and Alzheimer disease by serum 25(OH)D concentration</p></caption><graphic xlink:href='NEUROLOGY2014574723TT2'></graphic></table-wrap><fig id='F1' position='float'><label>Figure 1</label><caption><title>Kaplan-Meier curves for unadjusted rates of all-cause dementia and Alzheimer disease by serum 25-hydroxyvitamin D (25(OH)D) concentrations.</title></caption><graphic xlink:href='NEUROLOGY2014574723FF1'></graphic></fig><fig id='F2' position='float'><label>Figure 2</label><caption><title>Multivariate adjusted smoothing spline plots showing the hazard ratios for dementia and Alzheimer disease by serum 25(OH)D concentrations</title><p>Models adjusted for age, season of vitamin D collection, education, sex, body mass index, smoking, alcohol consumption, and depressive symptoms. Hazard ratios centered on median serum 25-hydroxyvitamin D (25(OH)D) concentrations.</p></caption><graphic xlink:href='NEUROLOGY2014574723FF2'></graphic></fig><p><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Secondary analyses incorporating continuous 25(OH)D concentrations gave a similar pattern of results.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The multivariate adjusted risks for incident all-cause dementia and incident AD reduced by 18% (hazard ratio [HR] = 0.82, 95% confidence interval [CI]: 0.70–0.97, <italic>p</italic> = 0.02) and 20% (HR = 0.80, 95% CI: 0.65–0.99, <italic>p</italic> = 0.04), respectively, for each 1 SD increase in log-transformed 25(OH)D.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Additional adjustment for diabetes or hypertension did not change the pattern of results for either incident all-cause dementia or AD, suggesting that these conditions are unlikely to mediate the observed associations (<xref rid='T3' ref-type='table'>table 3</xref>).</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Adjustment for ethnicity attenuated the main results slightly but did not change the overall pattern of results, and there were no significant interactions (table e-1 on the <italic>Neurology®</italic> Web site at <ext-link ext-link-type='uri' xlink:href='http://Neurology.org'>Neurology.org</ext-link>).</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Additional adjustment for income and occupation did not change the associations either (table e-2).</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The odds of prevalent all-cause dementia and AD at baseline in participants who were severely 25(OH)D deficient were 3–6 times higher than those with sufficient 25(OH)D, with a linear trend across groups (table e-3).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> After excluding participants who developed all-cause dementia and AD within 1 year of baseline, the multivariate adjusted HRs in participants who were severely 25(OH)D deficient and deficient compared to participants with sufficient 25(OH)D concentrations were 2.42 (95% CI: 1.33–4.39) and 1.54 (95% CI: 1.06–2.28) for incident all-cause dementia (<italic>p</italic> for linear trend = 0.001) and 2.36 (95% CI: 1.08–5.16) and 1.69 (95% CI: 1.04–2.73) for AD (<italic>p</italic> for linear trend = 0.007).</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This suggests that the association is not driven by “early converters.”</s></p><table-wrap id='T3' position='float'><label>Table 3</label><caption><p>Cox proportional hazards regression models of incident all-cause dementia and Alzheimer disease by serum 25(OH)D concentration with additional adjustment for potential mediators</p></caption><graphic xlink:href='NEUROLOGY2014574723TT3'></graphic></table-wrap></sec><sec sec-type='discussion' id='s3'><title>DISCUSSION</title><p><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>We have conducted what is to our knowledge the first large, prospective, population-based study to examine vitamin D concentrations in relation to a comprehensive adjudicated assessment of dementia and AD.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We observed a strong monotonic association between 25(OH)D concentrations and the risk of both incident all-cause dementia and AD.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This association was robust to adjustment for a range of potential confounders and the exclusion of dementia cases that occurred within a year of baseline.</s></p><p><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The 2 previous studies that have investigated vitamin D and incident dementia have produced conflicting results.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The first found that severe vitamin D deficiency was associated with non-AD dementia but not AD risk.<sup><xref rid='R16' ref-type='bibr'>16</xref></sup></s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The second found that severe vitamin D deficiency was associated with AD but not vascular dementia risk.<sup><xref rid='R17' ref-type='bibr'>17</xref></sup></s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, the first study incorporated a small sample of high-functioning women (n = 40), and the lack of association with AD may reflect limited statistical power.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The second study relied on registry data for dementia diagnoses, which may have resulted in considerable misclassification.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results establish that low 25(OH)D concentrations are linked to an increased risk of incident all-cause dementia and AD, and they are consistent with studies suggesting a link with cognitive impairment<sup><xref rid='R1' ref-type='bibr'>1</xref>,<xref rid='R3' ref-type='bibr'>3</xref>,<xref rid='R12' ref-type='bibr'>12</xref>,<xref rid='R26' ref-type='bibr'>26</xref>,<xref rid='R28' ref-type='bibr'>28</xref></sup> and cognitive decline.<sup><xref rid='R13' ref-type='bibr'>13</xref><xref rid='R14' ref-type='bibr'>–</xref><xref rid='R15' ref-type='bibr'>15</xref></sup></s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Few studies have examined potential mediators of this association, although there was no evidence in the present study or the InCHIANTI<sup><xref rid='R13' ref-type='bibr'>13</xref></sup> study for mediation by diabetes or hypertension.</s></p><p><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A threshold below which the risk of dementia increases markedly has previously been hypothesized to lie in the 25–50 nmol/L range.<sup><xref rid='R12' ref-type='bibr'>12</xref></sup></s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The optimal level of vitamin D for general health remains controversial, with the Institute of Medicine recommending 50 nmol/L and the Endocrine Society recommending 75 nmol/L.<sup><xref rid='R29' ref-type='bibr'>29</xref>,<xref rid='R30' ref-type='bibr'>30</xref></sup></s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A post hoc analysis of the Women's Health Initiative randomized controlled trial discovered that a relatively low dose of vitamin D (400 IU) in combination with calcium (1,000 mg) did not protect against dementia over a mean follow-up period of 7.8 years in women who had relatively high serum vitamin D levels at baseline (mean of 49 nmol/L in a small subsample).<sup><xref rid='R31' ref-type='bibr'>31</xref></sup></s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results clarify that the threshold above which older adults are unlikely to benefit from supplementation with regard to dementia risk is likely to lie in the region of 50 nmol/L when 25(OH)D concentrations are measured using LC-MS.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This therefore adds to the ongoing debate regarding optimal vitamin D levels for different health outcomes.</s></p><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A number of potential mechanisms linking low vitamin D levels with the risk of dementia have been identified.<sup><xref rid='R32' ref-type='bibr'>32</xref></sup></s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Vitamin D receptors are expressed throughout the brain, including areas involved in memory such as the hippocampus and dentate gyrus.<sup><xref rid='R6' ref-type='bibr'>6</xref></sup></s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Similarly, the enzyme that synthesizes the active form of vitamin D, 1α-hydroxylase, is produced in several cerebral regions.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The active form of vitamin D, 1,25dihydroxy-vitamin D3 (1,25-D3), regulates neurotrophin expression, such as nerve growth factor, neurotrophin 3, and glial-derived neurotrophic factor,<sup><xref rid='R11' ref-type='bibr'>11</xref></sup> and the survival, development, and function of neural cells.<sup><xref rid='R33' ref-type='bibr'>33</xref></sup></s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In vitro, vitamin D stimulates macrophages, which increases the clearance of amyloid plaques, a hallmark of AD.<sup><xref rid='R7' ref-type='bibr'>7</xref>,<xref rid='R8' ref-type='bibr'>8</xref></sup></s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Vitamin D also reduces amyloid-induced cytotoxicity and apoptosis in primary cortical neurons.<sup><xref rid='R9' ref-type='bibr'>9</xref></sup></s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A recent study found that amyloid-β induction of induced nitric oxide synthase, part of the inflammatory process of AD, is dependent on the disruption of the vitamin D-vitamin D receptor pathway.<sup><xref rid='R34' ref-type='bibr'>34</xref></sup></s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Vitamin D supplementation ameliorates age-related decline in learning and memory in aged rats.<sup><xref rid='R35' ref-type='bibr'>35</xref></sup></s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, vitamin D deficiency has been linked to cerebrovascular pathology.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Meta-analyses establish that 25(OH)D deficiency is associated with an increased risk of incident stroke,<sup><xref rid='R36' ref-type='bibr'>36</xref></sup> particularly ischemic stroke.<sup><xref rid='R10' ref-type='bibr'>10</xref></sup></s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A cross-sectional study of 318 elderly adults found that 25(OH)D deficiency was associated with increased white matter hyperintensity volume and a greater number of large vessel infarcts.<sup><xref rid='R37' ref-type='bibr'>37</xref></sup></s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In summary, low vitamin D concentrations may increase the risk of dementia and AD through both neurodegenerative and vascular mechanisms.</s></p><p><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Our study has a number of strengths.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The study sample was relatively diverse as it was population-based and included white and African-American men and women.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A recent systematic review raised the possibility that the consistent observational associations between vitamin D levels and a wide range of health conditions may simply reflect reverse causation.<sup><xref rid='R38' ref-type='bibr'>38</xref></sup></s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> However, in this study reverse causation is made less likely by the fact that participants were ambulatory and relatively healthy at baseline (their outdoor activity was not likely to be limited by impaired function linked to the onset of dementia).</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The long follow-up and exclusion of prevalent dementia and incident dementia occurring within a year of baseline also make reverse causation less likely.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All-cause dementia and AD in the CHS were diagnosed by a committee of neurologists and psychiatrists using a comprehensive range of data, including neuroimaging, according to international criteria (NINCDS-ADRDA).<sup><xref rid='R23' ref-type='bibr'>23</xref></sup></s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Our study also has several limitations.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> While the CHS is multiethnic, it did not incorporate people of Hispanic or other ethnicities.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Due to the exclusion of participants with cardiovascular disease and stroke at baseline, there were few cases of incident vascular dementia (n = 15).</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It was therefore not possible to investigate the relationship between vitamin D concentrations and incident vascular dementia due to a lack of statistical power, and further research is necessary to investigate generalizability to older adults with vascular dysfunction.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> In a cohort with a greater burden of vascular and metabolic dysfunction it would also be interesting to investigate these factors as time-varying covariates.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The representativeness of our final sample may have been reduced due to the inability to include participants with insufficient serum volume for 25(OH)D measurement (n = 945) as well as those lost to follow-up (n = 596).</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> It is possible that the delay between obtaining the blood samples in 1992–1993 and measuring 25(OH)D concentrations in 2008 could have introduced measurement error; however, this is unlikely to have introduced systematic bias.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Despite the wide range of information (including repeat neuroimaging) available to the committee diagnosing all-cause dementia and AD, a degree of misclassification is still likely.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In particular, many cases of AD may actually reflect a mixture of pathologies, so caution should be exercised when considering potential mechanisms.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> As with all observational studies, unmeasured confounding is possible, and our findings do not in themselves demonstrate a causal relationship.</s></p><p><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>We found a strong association between baseline vitamin D concentrations and the risk of incident all-cause dementia and AD over a mean of 5.6 years of follow-up in ambulatory older adults free from vascular conditions at baseline.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Further studies are necessary to replicate our findings and extend them to more diverse populations.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> It would be useful to conduct prospective studies to investigate the association between vitamin D concentrations and incident vascular dementia and neuroimaging abnormalities.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our findings support the hypothesis that vitamin D may be neuroprotective and that “sufficiency” in the context of dementia risk may be in the region of 50 nmol/L.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This information is likely to prove useful in improving the design and reducing the cost of randomized controlled trials investigating whether vitamin D supplements can be used to delay or prevent the onset of dementia and AD in older adults.</s></p></sec><sec sec-type='supplementary-material'><title>Supplementary Material</title><supplementary-material content-type='local-data' id='PMC_1'><caption><title>Data Supplement</title></caption><media mime-subtype='html' mimetype='text' xlink:href='supp_83_10_920__index.html'></media><media mime-subtype='msword' mimetype='application' xlink:role='associated-file' xlink:href='supp_WNL.0000000000000755_Tables_e-1-3.docx'></media></supplementary-material></sec></body><back><fn-group><fn fn-type='supplementary-material'><p>Supplemental data at <ext-link ext-link-type='uri' xlink:href='http://neurology.org/'>Neurology.org</ext-link></p></fn></fn-group><sec sec-type='contributions'><title>AUTHOR CONTRIBUTIONS</title><p content-type='contributions'>Mr. Littlejohns: drafting and revising the manuscript for content, study concept and design, analysis and interpretation of data, and statistical analysis. Dr. Henley: revising the manuscript for content, study concept and design, analysis and interpretation of data, and statistical analysis. Dr. Lang: revising the manuscript for content, interpretation of data. Dr. Annweiler: revising the manuscript for content, interpretation of data. Dr. Beauchet: revising the manuscript for content, interpretation of data. Dr. Chaves: revising the manuscript for content, interpretation of data, obtaining funding. Dr. Fried: revising the manuscript for content, interpretation of data, acquisition of data. Dr. Kestenbaum: revising the manuscript for content, interpretation of data, acquisition of data, obtaining funding. Dr. Kuller: revising the manuscript for content, interpretation of data, acquisition of data. Dr. Langa: revising the manuscript for content, interpretation of data, acquisition of data, obtaining funding. Dr. Lopez: revising the manuscript for content, interpretation of data, acquisition of data. Dr. Kos: revising the manuscript for content, study concept and design, analysis and interpretation of data. Dr. Soni: revising the manuscript for content, study concept and design, analysis and interpretation of data, statistical analysis. Dr. Llewellyn: drafting and revising the manuscript for content, study concept and design, analysis and interpretation of data, acquisition of data, statistical analysis, study supervision and coordination, obtaining funding.</p></sec><sec sec-type='funding'><title>STUDY FUNDING</title><p content-type='funding'>The CHS was supported by contracts <award-id>HHSN268201200036C</award-id>, <award-id>HHSN268200800007C</award-id>, <award-id>N01 HC55222</award-id>, <award-id>N01HC85079</award-id>, <award-id>N01HC85080</award-id>, <award-id>N01HC85081</award-id>, <award-id>N01HC85082</award-id>, <award-id>N01HC85083</award-id>, <award-id>N01HC85086</award-id>, and grant <award-id>HL080295</award-id> from the National Heart, Lung, and Blood Institute, with additional contribution from the <funding-source>National Institute of Neurological Disorders and Stroke</funding-source>. Additional support was provided by <award-id>AG023629</award-id>, <award-id>AG20098</award-id>, <award-id>AG15928</award-id>, and <award-id>HL084443</award-id> from the <funding-source>National Institute on Aging</funding-source>. A full list of principal CHS investigators and institutions can be found at <ext-link ext-link-type='uri' xlink:href='http://www.chs-nhlbi.org'>www.chs-nhlbi.org</ext-link>. Additional support was also provided by NIRG-11-200737 from the Alzheimer's Association, the Mary Kinross Charitable Trust, the James Tudor Foundation, the Halpin Trust, the Age Related Diseases and Health Trust, and the Norman Family Charitable Trust (to D.J.L.). This report presents independent research supported by the <funding-source>UK National Institute for Health Research</funding-source> (<funding-source>NIHR</funding-source>) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South West Peninsula. None of the funding sources had any role in the design of the study; in the analysis and interpretation of the data; or in the preparation of the manuscript. The views expressed in this publication are those of the authors and not necessarily those of the <funding-source>NHS</funding-source>, the <funding-source>NIHR</funding-source>, or the Department of Health in England. The <funding-source>NIH</funding-source> was involved in the original design and conduct of the CHS and in the data collection methods.</p></sec><sec sec-type='disclosure'><title>DISCLOSURE</title><p content-type='disclosure'>The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type='uri' xlink:href='http://neurology.org/'>Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id='G1'>25(OH)D</term><def><p>25-hydroxyvitamin D</p></def></def-item><def-item><term id='G2'>AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term id='G3'>BMI</term><def><p>body mass index</p></def></def-item><def-item><term id='G4'>CHS</term><def><p>Cardiovascular Health Study</p></def></def-item><def-item><term id='G5'>CI</term><def><p>confidence interval</p></def></def-item><def-item><term id='G6'>HR</term><def><p>hazard ratio</p></def></def-item><def-item><term id='G7'>LC-MS</term><def><p>liquid chromatography-tandem mass spectrometry</p></def></def-item><def-item><term id='G8'>NINCDS-ADRDA</term><def><p>National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id='R1'><label>1.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Balion</surname><given-names>C</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Strifler</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Vitamin D, cognition, and dementia: a systematic review and meta-analysis</article-title>. <source>Neurology</source><year>2012</year>;<volume>79</volume>:<fpage>1397</fpage>–<lpage>1405</lpage><pub-id pub-id-type='pmid'>23008220</pub-id></mixed-citation></ref><ref id='R2'><label>2.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Beauchet</surname><given-names>O</given-names></name></person-group><article-title>Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis</article-title>. <source>J Alzheimers Dis</source><year>2013</year>;<volume>33</volume>:<fpage>659</fpage>–<lpage>674</lpage><pub-id pub-id-type='pmid'>23042216</pub-id></mixed-citation></ref><ref id='R3'><label>3.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Montero-Odasso</surname><given-names>M</given-names></name><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Richard-Devantoy</surname><given-names>S</given-names></name><name><surname>Duque</surname><given-names>G</given-names></name><name><surname>Beauchet</surname><given-names>O</given-names></name></person-group><article-title>Meta-analysis of memory and executive dysfunctions in relation to vitamin D</article-title>. <source>J Alzheimers Dis</source><year>2013</year>;<volume>37</volume>:<fpage>147</fpage>–<lpage>171</lpage><pub-id pub-id-type='pmid'>23948884</pub-id></mixed-citation></ref><ref id='R4'><label>4.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Vitamin D deficiency</article-title>. <source>N Engl J Med</source><year>2007</year>;<volume>357</volume>:<fpage>266</fpage>–<lpage>281</lpage><pub-id pub-id-type='pmid'>17634462</pub-id></mixed-citation></ref><ref id='R5'><label>5.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Thies</surname><given-names>W</given-names></name><name><surname>Bleiler</surname><given-names>L</given-names></name></person-group><article-title>2013 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source><year>2013</year>;<volume>9</volume>:<fpage>208</fpage>–<lpage>245</lpage><pub-id pub-id-type='pmid'>23507120</pub-id></mixed-citation></ref><ref id='R6'><label>6.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Eyles</surname><given-names>DW</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Kinobe</surname><given-names>R</given-names></name><name><surname>Hewison</surname><given-names>M</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name></person-group><article-title>Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain</article-title>. <source>J Chem Neuroanat</source><year>2005</year>;<volume>29</volume>:<fpage>21</fpage>–<lpage>30</lpage><pub-id pub-id-type='pmid'>15589699</pub-id></mixed-citation></ref><ref id='R7'><label>7.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Masoumi</surname><given-names>A</given-names></name><name><surname>Goldenson</surname><given-names>B</given-names></name><name><surname>Ghirmai</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients</article-title>. <source>J Alzheimers Dis</source><year>2009</year>;<volume>17</volume>:<fpage>703</fpage>–<lpage>717</lpage><pub-id pub-id-type='pmid'>19433889</pub-id></mixed-citation></ref><ref id='R8'><label>8.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mizwicki</surname><given-names>MT</given-names></name><name><surname>Menegaz</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Genomic and nongenomic signaling induced by 1α,25(OH)2-vitamin D3 promotes the recovery of amyloid-β phagocytosis by Alzheimer's disease macrophages</article-title>. <source>J Alzheimers Dis</source><year>2012</year>;<volume>29</volume>:<fpage>51</fpage>–<lpage>62</lpage><pub-id pub-id-type='pmid'>22207005</pub-id></mixed-citation></ref><ref id='R9'><label>9.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dursun</surname><given-names>E</given-names></name><name><surname>Gezen-Ak</surname><given-names>D</given-names></name><name><surname>Yilmazer</surname><given-names>S</given-names></name></person-group><article-title>A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons</article-title>. <source>J Alzheimers Dis</source><year>2011</year>;<volume>23</volume>:<fpage>207</fpage>–<lpage>219</lpage><pub-id pub-id-type='pmid'>20966550</pub-id></mixed-citation></ref><ref id='R10'><label>10.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brøndum-Jacobsen</surname><given-names>P</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Benn</surname><given-names>M</given-names></name></person-group><article-title>25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis</article-title>. <source>Ann Neurol</source><year>2013</year>;<volume>73</volume>:<fpage>38</fpage>–<lpage>47</lpage><pub-id pub-id-type='pmid'>23225498</pub-id></mixed-citation></ref><ref id='R11'><label>11.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Montero-Odasso</surname><given-names>M</given-names></name><name><surname>Hachinski</surname><given-names>V</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Bartha</surname><given-names>R</given-names></name><name><surname>Beauchet</surname><given-names>O</given-names></name></person-group><article-title>Vitamin D concentration and lateral cerebral ventricle volume in older adults</article-title>. <source>Mol Nutr Food Res</source><year>2013</year>;<volume>57</volume>:<fpage>267</fpage>–<lpage>276</lpage><pub-id pub-id-type='pmid'>23281306</pub-id></mixed-citation></ref><ref id='R12'><label>12.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dickens</surname><given-names>AP</given-names></name><name><surname>Lang</surname><given-names>IA</given-names></name><name><surname>Langa</surname><given-names>KM</given-names></name><name><surname>Kos</surname><given-names>K</given-names></name><name><surname>Llewellyn</surname><given-names>DJ</given-names></name></person-group><article-title>Vitamin D, cognitive dysfunction and dementia in older adults</article-title>. <source>CNS Drugs</source><year>2011</year>;<volume>25</volume>:<fpage>629</fpage>–<lpage>639</lpage><pub-id pub-id-type='pmid'>21790207</pub-id></mixed-citation></ref><ref id='R13'><label>13.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Lang</surname><given-names>IA</given-names></name><name><surname>Langa</surname><given-names>KM</given-names></name><etal></etal></person-group><article-title>Vitamin D and risk of cognitive decline in elderly persons</article-title>. <source>Arch Intern Med</source><year>2010</year>;<volume>170</volume>:<fpage>1135</fpage>–<lpage>1141</lpage><pub-id pub-id-type='pmid'>20625021</pub-id></mixed-citation></ref><ref id='R14'><label>14.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Slinin</surname><given-names>Y</given-names></name><name><surname>Paudel</surname><given-names>ML</given-names></name><name><surname>Taylor</surname><given-names>BC</given-names></name><etal></etal></person-group><article-title>25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men</article-title>. <source>Neurology</source><year>2010</year>;<volume>74</volume>:<fpage>33</fpage>–<lpage>41</lpage><pub-id pub-id-type='pmid'>19940271</pub-id></mixed-citation></ref><ref id='R15'><label>15.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Slinin</surname><given-names>Y</given-names></name><name><surname>Paudel</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>BC</given-names></name><etal></etal></person-group><article-title>Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2012</year>;<volume>67</volume>:<fpage>1092</fpage>–<lpage>1098</lpage><pub-id pub-id-type='pmid'>22454371</pub-id></mixed-citation></ref><ref id='R16'><label>16.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Annweiler</surname><given-names>C</given-names></name><name><surname>Rolland</surname><given-names>Y</given-names></name><name><surname>Schott</surname><given-names>AM</given-names></name><name><surname>Blain</surname><given-names>H</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Beauchet</surname><given-names>O</given-names></name></person-group><article-title>Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study</article-title>. <source>Dement Geriatr Cogn Disord</source><year>2011</year>;<volume>32</volume>:<fpage>273</fpage>–<lpage>278</lpage><pub-id pub-id-type='pmid'>22261995</pub-id></mixed-citation></ref><ref id='R17'><label>17.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Afzal</surname><given-names>S</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group><article-title>Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia</article-title>. <source>Alzheimers Dement</source><year>2014</year>;<volume>10</volume>:<fpage>296</fpage>–<lpage>302</lpage><pub-id pub-id-type='pmid'>23871764</pub-id></mixed-citation></ref><ref id='R18'><label>18.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Borhani</surname><given-names>NO</given-names></name><name><surname>Enright</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>The Cardiovascular Health Study: design and rationale</article-title>. <source>Ann Epidemiol</source><year>1991</year>;<volume>1</volume>:<fpage>263</fpage>–<lpage>276</lpage><pub-id pub-id-type='pmid'>1669507</pub-id></mixed-citation></ref><ref id='R19'><label>19.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kestenbaum</surname><given-names>B</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>de Boer</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Vitamin D, parathyroid hormone, and cardiovascular events among older adults</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>58</volume>:<fpage>1433</fpage>–<lpage>1441</lpage><pub-id pub-id-type='pmid'>21939825</pub-id></mixed-citation></ref><ref id='R20'><label>20.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Ives</surname><given-names>DG</given-names></name><etal></etal></person-group><article-title>Incidence and prevalence of dementia in the Cardiovascular Health Study</article-title>. <source>J Am Geriatr Soc</source><year>2004</year>;<volume>52</volume>:<fpage>195</fpage>–<lpage>204</lpage><pub-id pub-id-type='pmid'>14728627</pub-id></mixed-citation></ref><ref id='R21'><label>21.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>De Boer</surname><given-names>IH</given-names></name><name><surname>Levin</surname><given-names>G</given-names></name><name><surname>Robinson-Cohen</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study</article-title>. <source>Ann Intern Med</source><year>2012</year>;<volume>156</volume>:<fpage>627</fpage>–<lpage>634</lpage><pub-id pub-id-type='pmid'>22547472</pub-id></mixed-citation></ref><ref id='R22'><label>22.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Phinney</surname><given-names>KW</given-names></name></person-group><article-title>Development of a standard reference material for vitamin D in serum</article-title>. <source>Am J Clin Nutr</source><year>2008</year>;<volume>88</volume>:<fpage>511S</fpage>–<lpage>512S</lpage><pub-id pub-id-type='pmid'>18689392</pub-id></mixed-citation></ref><ref id='R23'><label>23.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Fitzpatrick</surname><given-names>A</given-names></name><name><surname>Ives</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Beauchamp</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of dementia in the cardiovascular health cognition study</article-title>. <source>Neuroepidemiology</source><year>2003</year>;<volume>22</volume>:<fpage>1</fpage>–<lpage>12</lpage><pub-id pub-id-type='pmid'>12566948</pub-id></mixed-citation></ref><ref id='R24'><label>24.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Radloff</surname><given-names>L</given-names></name></person-group><article-title>The CES-D scale: a self-report depression scale for research in the general population</article-title>. <source>Appl Psychol Meas</source><year>1977</year>;<volume>1</volume>:<fpage>385</fpage>–<lpage>401</lpage></mixed-citation></ref><ref id='R25'><label>25.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schoenfeld</surname><given-names>D</given-names></name></person-group><article-title>Partial residuals for the proportional hazards regression model</article-title>. <source>Biometrika</source><year>1982</year>;<volume>69</volume>:<fpage>239</fpage>–<lpage>241</lpage></mixed-citation></ref><ref id='R26'><label>26.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Lang</surname><given-names>IA</given-names></name><name><surname>Langa</surname><given-names>KM</given-names></name><name><surname>Melzer</surname><given-names>D</given-names></name></person-group><article-title>Vitamin D and cognitive impairment in the elderly U.S. population</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2011</year>;<volume>66</volume>:<fpage>59</fpage>–<lpage>65</lpage><pub-id pub-id-type='pmid'>21041201</pub-id></mixed-citation></ref><ref id='R27'><label>27.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brehm</surname><given-names>JM</given-names></name><name><surname>Schuemann</surname><given-names>B</given-names></name><name><surname>Fuhlbrigge</surname><given-names>AL</given-names></name><etal></etal></person-group><article-title>Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study</article-title>. <source>J Allergy Clin Immunol</source><year>2010</year>;<volume>126</volume>:<fpage>52</fpage>–<lpage>58.e5</lpage><pub-id pub-id-type='pmid'>20538327</pub-id></mixed-citation></ref><ref id='R28'><label>28.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Llewellyn</surname><given-names>D</given-names></name><name><surname>Langa</surname><given-names>K</given-names></name></person-group><article-title>Serum 25-hydroxyvitamin D concentration and cognitive impairment</article-title>. <source>J Geriatr Psychiatry</source><year>2009</year>;<volume>22</volume>:<fpage>188</fpage>–<lpage>195</lpage></mixed-citation></ref><ref id='R29'><label>29.</label><mixed-citation publication-type='book'><collab>Institute of Medicine</collab>. <source>Dietary Reference Intakes for Calcium and Vitamin D</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2011</year></mixed-citation></ref><ref id='R30'><label>30.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Binkley</surname><given-names>NC</given-names></name><name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name><etal></etal></person-group><article-title>Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source><year>2011</year>;<volume>96</volume>:<fpage>1911</fpage>–<lpage>1930</lpage><pub-id pub-id-type='pmid'>21646368</pub-id></mixed-citation></ref><ref id='R31'><label>31.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rossom</surname><given-names>RC</given-names></name><name><surname>Espeland</surname><given-names>MA</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative</article-title>. <source>J Am Geriatr Soc</source><year>2012</year>;<volume>60</volume>:<fpage>2197</fpage>–<lpage>2205</lpage><pub-id pub-id-type='pmid'>23176129</pub-id></mixed-citation></ref><ref id='R32'><label>32.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gezen-Ak</surname><given-names>D</given-names></name><name><surname>Yilmazer</surname><given-names>S</given-names></name><name><surname>Dursun</surname><given-names>E</given-names></name></person-group><article-title>Why vitamin D in Alzheimer's disease? the hypothesis</article-title>. <source>J Alzheimers Dis</source><year>2014</year>;<volume>40</volume>:<fpage>257</fpage>–<lpage>269</lpage><pub-id pub-id-type='pmid'>24413618</pub-id></mixed-citation></ref><ref id='R33'><label>33.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fernandes de Abreu</surname><given-names>DA</given-names></name><name><surname>Eyles</surname><given-names>D</given-names></name><name><surname>Féron</surname><given-names>F</given-names></name></person-group><article-title>Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases</article-title>. <source>Psychoneuroendocrinology</source><year>2009</year>;<volume>34</volume>(<issue>suppl 1</issue>):<fpage>S265</fpage>–<lpage>S277</lpage><pub-id pub-id-type='pmid'>19545951</pub-id></mixed-citation></ref><ref id='R34'><label>34.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dursun</surname><given-names>E</given-names></name><name><surname>Gezen-Ak</surname><given-names>D</given-names></name><name><surname>Yilmazer</surname><given-names>S</given-names></name></person-group><article-title>A new mechanism for amyloid-β induction of iNOS: vitamin D-VDR pathway disruption</article-title>. <source>J Alzheimers Dis</source><year>2013</year>;<volume>36</volume>:<fpage>459</fpage>–<lpage>474</lpage><pub-id pub-id-type='pmid'>23624519</pub-id></mixed-citation></ref><ref id='R35'><label>35.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Briones</surname><given-names>TL</given-names></name><name><surname>Darwish</surname><given-names>H</given-names></name></person-group><article-title>Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden</article-title>. <source>J Neuroinflammation</source><year>2012</year>;<volume>9</volume>:<fpage>244</fpage><pub-id pub-id-type='pmid'>23098125</pub-id></mixed-citation></ref><ref id='R36'><label>36.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies</article-title>. <source>Circ Cardiovasc Qual Outcomes</source><year>2012</year>;<volume>5</volume>:<fpage>819</fpage>–<lpage>829</lpage><pub-id pub-id-type='pmid'>23149428</pub-id></mixed-citation></ref><ref id='R37'><label>37.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Buell</surname><given-names>JS</given-names></name><name><surname>Weiner</surname><given-names>DE</given-names></name><name><surname>Tucker</surname><given-names>L</given-names></name><name><surname>Usda</surname><given-names>JM</given-names></name></person-group><article-title>25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services</article-title>. <source>Neurology</source><year>2010</year>;<volume>74</volume>:<fpage>18</fpage>–<lpage>26</lpage><pub-id pub-id-type='pmid'>19940273</pub-id></mixed-citation></ref><ref id='R38'><label>38.</label><mixed-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Autier</surname><given-names>P</given-names></name><name><surname>Boniol</surname><given-names>M</given-names></name><name><surname>Pizot</surname><given-names>C</given-names></name><name><surname>Mullie</surname><given-names>P</given-names></name></person-group><article-title>Vitamin D status and ill health: a systematic review</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2014</year>;<volume>2</volume>:<fpage>76</fpage>–<lpage>89</lpage><pub-id pub-id-type='pmid'>24622671</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>